Shreeshiddivinayak Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 4 Year, 6 Months
- Last Filing with ROC 31 Mar 2022
- Revenue Growth 615.24%
- Profit Growth 515.20%
- Ebitda 1443.77%
- Net Worth 2.66%
- Total Assets 80.38%
About Shreeshiddivinayak Pharmaceuticals
Shreeshiddivinayak Pharmaceuticals Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 14 August 2020 (Four years and six months 2 days old ). Its registered office is in Gwalior, Madhya Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Shashi Tomar and Ravi Tomar serve as directors at the Company.
Company Details
-
Location
Gwalior, Madhya Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24230MP2020PTC052335
-
Company No.
052335
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
14 Aug 2020
-
Date of AGM
30 Sep 2022
-
Date of Balance Sheet
31 Mar 2022
-
Listing Status
Unlisted
-
ROC Code
Roc Gwalior
Industry
Who are the key members and board of directors at Shreeshiddivinayak Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shashi Tomar
|
Director | 14-Aug-2020 | Current |
|
Ravi Tomar
|
Director | 14-Aug-2020 | Current |
Financial Performance of Shreeshiddivinayak Pharmaceuticals.
Shreeshiddivinayak Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 615.24% increase. The company also saw a substantial improvement in profitability, with a 515.2% increase in profit. The company's net worth moved up by a moderate rise of 2.66%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Shreeshiddivinayak Pharmaceuticals?
In 2022, Shreeshiddivinayak Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Shreeshiddivinayak Medicare Private LimitedShashi Tomar is a mutual person
-
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Shreeshiddivinayak Pharmaceuticals?
Shreeshiddivinayak Pharmaceuticals has a workforce of 0 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Shreeshiddivinayak Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shreeshiddivinayak Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.